October 18, 2019 8:24am
… And “Fall from the sky with melted wings”
The realty is who cares, we know he drops into the sea; the likely response is how much of a splash was made by his crash is what investors will ask!
An analogy with a little alliteration about our cell and gene therapy sector
Insight is about understanding perception and is putting into context what is relevant to expectation fulfillment …
But cannot be imaginative in considering explanations for missing, confusing and often contradictory data while human analysis is able to identify one’s own biases and expectation of what the data might/should/could show!
Dow futures are UP +0.09% (+23 points), S&P futures are UP +0.08% (+3 points) and NASDAQ futures are UP +0.03% (+2 points)
U.S. stock index futures were little changed in early trading Friday as investors were set to wrap up the first week of the earnings season;
European stocks traded lower as traders seek signals as to whether a Brexit deal agreed between the U.K. and EU will pass muster with British lawmakers in parliament as the pan-European Stoxx 600 pared early losses to trade 0.2% lower by mid-morning;
Asia Pacific markets mostly declined as China released worse-than-expected gross domestic product figures, impacted by Beijing’s protracted trade conflict with the U.S. with MSCI’s broadest index of Asia-Pacific shares outside Japan was down -0.30%.
Data docket: None
It’s not about our cell and gene therapy sector to be concerned for the upside to continue – it’s dependent without news or the lack of and about the surrounding macro conditions.
For the week, the Dow (+0.8%), the S&P 500 (+0.9) and NASDAQ (+1.2%) were up for the week through Thursday’s close. Brexit also gave stocks a boost this week. The U.K. and European Union struck a long-awaited draft Brexit deal. China posted its weakest growth in nearly three decades, as the U.S.-China trade war hit demand at home and abroad. China, second-largest economy grew 6% in the third quarter, less than expected, and its weakest pace of expansion in over 27 years.
But, concerns over the state of our micro world of cell and gene therapy companies and its economics (funding, funding and funding) lingered.
It’s Friday, have you been marinating the olives in the potatoes derived elixir?
You’ll need it …
Thursday night’s newsletter heading: “three (3) up sessions and counting. Volume (versus 3 month averages) is still low along with percentage moves.”
- The NASDAQ closed UP +32.67 points (+0.40%)
- The IBB closed up +0.68% while the XBI closed up +0.86% after Wednesday’s IBB -0.11% and the XBI closing down -0.13%
- The close was positive with an A/D line of 25/17, 0 flat, 1 reversed merged (HSGX) and 2 acquired;
- The range of the 25 upside was +0.31% (ONVO) to +2.85% (SAGE) while the 17 downside ranged from -0.06% () to -6.16% (XON);
- 3 out of the 25 upside had higher than the 3 month average volume;
- 5 out of the 17 downside had higher than the 3 month average volume;
- October registered 7 positive, 1 neutral and 6 negative close, so far …
- September, there were 1 holiday, 11 negative, 7 positive and 2 non reported sessions;
Companies in my headlights – It’s your decision; I provide an idea and context:
*** I haven’t changed … follow the trading herd but … mindful of upcoming quarterly results and their effect upon share pricing … BUY and get trampled in the coming sessions or SELL into strength or just HOLD and wait to resolve relieve the anxiety until value returns.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.